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Abstract
Background: The pre-leukemia transcription factor 3 (PBX) is part of the PBX family of transcription factors, which
is known to regulate genes involved in differentiation of urogenital organs and steroidogenesis. This is of interest
with regard to prostate cancer progression as regulation of steroidogenesis is one of the mechanisms involved in
the development of castration-resistant prostate cancer. In light of this we wanted to investigate the possible
involvement of androgen regulation of PBX3 expression in prostate cancer.
Results: In this study, we show that PBX3 is post-transcriptionally regulated by androgen in prostate cancer cells
and that the effect might be independent of the androgen receptor. Furthermore, PBX3 was identified as a target
of Let-7d, an androgen regulated microRNA. Let-7d was down-regulated in malignant compared to benign
prostate tissue, whereas up-regulation of PBX3 expression was observed.
Conclusions: We demonstrate that PBX3 is up-regulated in prostate cancer and post- transcriptionally regulated by
androgen through Let-7d.
Background
Transcription factors play a pivotal role in carcinogen-
esis due to their function as activators and repressors of
gene expression. This key function also highlights their
potential role as candidate drug targets and prognostic
or diagnostic markers.
The Pre-B-cell leukemia transcription factors (PBX)
are members of the TALE (three amino acid loop exten-
sion) homeobox gene family. They are involved in regu-
lation of developmental gene expression, differentiation
of urogenital organs and steroidogenesis through their
abilities to form hetero-oligomeric DNA complexes
[1,2]. PBX proteins interact with a subset of HOX pro-
teins and with the Meinox subfamily of TALE class pro-
teins to enhance their DNA-binding affinities and
specificities. Human PBX1 was originally identified as a
proto-oncogene in pre-B cell acute lymphoblastic leuke-
mia where it is expressed as a fusion protein with E2A
after a chromosomal translocation [3,4]. Later PBX2,
PBX3 and PBX4 were identified as other members of
the PBX family based on their high degree of sequence
homology within and flanking their DNA-binding home-
odomains [5,6]. Alternative splicing of PBX transcripts
gives rise to high molecular weight (PBX1a, PBX2,
PBX3a and PBX4) and low molecular weight (PBX1b
and PBX3b, c, d) proteins [7].
Biochemical studies and expression profiling of PBX
proteins indicate that they have both overlapping and
specific functions [1]. Both PBX1 and PBX3 are
expressed in the cortex of developing adrenal glands
where they play a significant role in regulation of steroi-
dogenesis [8,9]. More specifically, PBX has been shown
to mediate ACTH-induced expression of CYP17A1
(cytochrome P-450 17alpha-hydroxylase), a key enzyme
required for cortisol and androgen biosynthesis [10].
Members of the PBX family have also been shown to
regulate metabolism of androgens in prostate cancer
cells by modulating the expression of UGT2B17, an
enzyme involved in glucuronidation of androgens [11].
PBX3 is highly expressed in developing central ner-
vous system (CNS), but otherwise expressed at low level
in the early phase of mouse organogenesis. Furthermore
as a consequence of its role in the CNS, mice that are
PBX3 deficient develop to term but die within a few
hours due to central respiratory failure. Later, PBX3
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becomes more widely expressed in epithelial and
mesenchymal tissue throughout the embryo [12].
As regulation of steroidogenesis is one of the mechan-
isms involved in the development of castration-resis-
tance prostate cancer, we wanted to study expression
and regulation of PBX3 in prostate cancer. Furthermore,
previous studies postulated that the PBX expression pat-
tern could be used as a tool for both stratification and
treatment of patients with cancer [13]. One possible
treatment option is to use synthetic peptides that func-
tion as antagonists by blocking the HOX/PBX dimer
formation. This approach has been reported to inhibit
proliferation of ovarian, renal, non-small-cell lung can-
cer and pancreatic cancer cell lines [14-17].
Results
Androgen regulation of PBX3 at protein level in prostate
cancer cell lines
In order to determine whether PBX3 expression is
androgen regulated at the protein level, we stimulated
LNCaP cells with 10-10 M R1881, a synthetic androgen
analogue, for 1 to 4 days followed by protein extraction
and Western analysis using an anti-human PBX3 anti-
body. Down-regulation of PBX3 was detected after 24
hours of R1881 stimulation, and was further reduced
after 4 days of treatment (Figure 1A). The androgen reg-
ulation of PBX3 was also observed in LNCaP C4-2B
(C4-2B) and RWPE-1 cell lines (Figure 1B), and when
LNCaP cells were stimulated with dihydrotestosterone
(Additional file 1: Fig.S1). Over-expression of PBX3 by
transfection of LNCaP cells (Figure 1A) and competition
with a competitor peptide (data not shown) were used
to confirm the specificity of the anti-PBX3 antibody.
The level of PBX3 was unchanged in untreated LNCaP-
cells during the experimental period (data not shown).
Androgen receptor independent regulation of PBX3
In order to explore the role of the androgen receptor
(AR) in androgen regulation of PBX3, LNCaP cells
were stimulated with R1881 in the absence and pre-
sence of bicalutamide (Bic), an AR antagonist (Figure
2A). A minor reduction in PBX3 level was seen in the
presence of bicalutamide alone and further reduction
was observed by adding R1881. Transfection of LNCaP
cells with siRNA targeting AR had no effect on the
level of PBX3, whereas the level of AR itself and
NKX3.1, a known androgen regulated gene, was
reduced (Figure 2B).
Post-transcriptional regulation of PBX3 by androgen
Interestingly, no significant change in PBX3 mRNA level
was detected between control (CSS) and androgen-sti-
mulated (R1881) LNCaP cells, and no effect of
bicalutamide (Bic) was observed (Additional file 2: Fig.
S2A). To determine whether androgen affects protein
synthesis and/or degradation of PBX3 at the protein
level, LNCaP cells were androgen stimulated in the pre-
sence or absence of cycloheximide, an inhibitor of pro-
tein synthesis. No significant effect of androgen was
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Figure 1 Androgen regulation of PBX3 in prostate cancer cell
lines. LNCaP cells were stimulated with 10-10M R1881 (R1881) or left
untreated (CSS) for 1 - 4 days before protein were extracted. A)
Representative Western blots probed with anti-human PBX3
antibody (upper panel) and anti-a-tubulin antibody as loading
control (lower panel) are shown. The lane to the right shows LNCaP
cells transfected with a PBX3 expression plasmid (PBX3-SPORT6).
Results of densitometric analysis of the PBX3 band relative to CSS
are shown in the histogram above. B) Representative Western blots
of C4-2B and RWPE-1 cells stimulated with 10-10M R1881 and
probed with anti-PBX3 antibody are shown in the upper panels.
Anti-a-tubulin antibody (C4-2B) or anti-PRKAR1A antibody (RWPE-1)
are shown as loading controls (lower panels). Data were obtained
from three independent experiments and are presented in the
histograms as mean ± SD (n = 3). A t-test (paired two samples of
mean) was performed and a two-tailed p-value < 0, 05 is indicated
with a *.
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observed on PBX3 expression level when protein synth-
esis was inhibited. This indicates that androgen may
affect translation/synthesis of PBX3 or that androgen
indirectly regulates the protein stability of PBX3 (Addi-
tional file 2: Fig.S2B).
Let-7d regulates PBX3 in LNCaP cells
One possible mechanism through which androgen may
regulate protein synthesis of PBX3 is through micro-
RNA that preferentially acts by binding to the 3 ’
untranslated region (3 ’UTR) of specific mRNAs.
MicroRNA that might regulate PBX3 expression was
identified by in silico analyses using three different
bioinformatic analysis software packages available,
miRANDA, TargetScan and PicTar [18-20]. Putative
binding sites for Let-7d, miR-101 and miR-222 were
identified in the 3’UTR of PBX3 with all three bioin-
formatic programs (Table 1). Transfection of LNCaP
cells with the three microRNAs identified in silico
showed that Let-7d mimic decreased the endogenous
protein level of PBX3 48 hours post-transfection,
demonstrating that Let-7d potentially regulates PBX3
expression (Figure 3A). MiR-101 and miR-222
appeared not to have any effect on the level of PBX3
in LNCaP cells. A modest up-regulation of PBX3 was
observed when transfecting LNCaP cells with a Let-7d
mimic hairpin inhibitor (Anti-Let-7d), that blocks Let-
7d microRNA (Figure 3A). Transfection of C4-2B and
RWPE-1 cells with Let-7d mimic down-regulated the
expression of endogenous PBX3 (Figure 3B).
The putative Let-7d binding site in the 3’UTR region
of PBX3 is depicted in Figure 4A. The 3’UTR sequence
of PBX3 was cloned into the pMIR-Luc plasmid and
transfected into LNCaP cells. The presence of the PBX3
3’UTR (pMIR-Luc-PBX3-3’UTR) reduced the luciferase
activity compared to an empty reporter plasmid (pMIR-
Luc), as would be expected if microRNA regulated the
expression of PBX3 (Figure 4B). No significant effect
was observed when the 3’UTR PBX3 sequence was
cloned into pMIR-Luc in the reverse orientation (pMIR-
Luc-PBX3-Rev3’UTR). To test whether Let-7d regulated
PBX3 expression, the reporter construct, pMIR-Luc-
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Figure 2 Androgen receptor independent regulation of PBX3 by
R1881. A) LNCaP cells were pre-treated for 3 days with medium
containing 10% CSS. Cells were then stimulated with 10-10M R1881
(R1881) and/or 10-8M bicalutamide (R1881 + Bic or Bic) or left
untreated (CSS) for 4 days. Total protein extracts were analyzed by
Western blotting using an anti-PBX3 antibody and anti-ERK 1/2 as
loading control. Results of densitometric analysis of the PBX3 band
relative to CSS are shown in the histogram. B) LNCaP cells were
transfected with a small interfering RNA against androgen receptor
(siRNA AR) and analyzed for PBX3 expression 48 hours post-
transfection. A non-specific small interfering RNA (siRNA Ctr.) was used
as control. Representative Western blots probed with anti-PBX3-, anti-
AR-, anti-NKX3.1- and anti-a-tubulin antibodies are shown in the figure.
The histograms depicts the results from densitometric analyses of
PBX3 and AR relative to siRNA Ctr. Data were obtained from three
independent experiments and are presented in the histograms as
mean ± SD (n = 3). A t-test (paired two samples of mean) was
performed and a two-tailed p-value < 0, 05 is indicated with a *.
Table 1 Predicted microRNA binding sites in PBX3 3’UTR
region
microRNA miRANDA TargetScan PicTar Prostate Cancer
miR-23a + ND ND +
miR-92 a/b + ND ND +
miR-101 + + + +
miR-202 + ND ND +
miR-222 + + + +
miR-320 ND + ND +
let-7a ND + ND +
let-7d + + + +
let-7g ND + ND +
A list of differentially regulated microRNAs in benign and malignant prostate
tissue was generated and potential binding sites in the PBX3 3’UTR region
were identified using microRNA target prediction software. ND indicates that
no binding site was detected/predicted by the software. The column marked
Prostate Cancer indicates that the microRNA has been reported to be
differentially regulated in benign and malignant prostate tissue.
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PBX3-3’UTR, was co-transfected with Let-7d mimic into
LNCaP cells. Co-transfection of Let-7d mimic reduced
the luciferase activity generated by pMIR-Luc-PBX3-
3’UTR (Figure 4C). The effect of Let-7d was blocked by
mutating the putative binding site of Let-7d in the
3’UTR sequence of PBX3 (PBX3 3’UTRmut).
Androgen regulation of Let-7d in prostate cancer cell
lines
Androgen regulation of PBX3 via Let-7d was further
explored by measuring Let-7d levels after R1881 stimu-
lation. LNCaP, C4-2B and RWPE-1 cells were stimu-
lated with 10-10 M R1881 for 24 hours and the level of
Let-7d was measured by sqRT-PCR. As shown in Figure
5 there was an up-regulation of Let-7d after 24 hours of
androgen treatment relative to unstimulated cells.
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Figure 3 MicroRNA regulation of endogenous PBX3 expression.
A) LNCaP cells were transfected with 5·10-8M miR-101, miR-222, Let-
7d or control mimic microRNA (Ctr.) as shown in the left panel. The
right panel shows transfection of LNCaP cells with 10-7M Let-7d
mimic Hairpin Inhibitor. Total protein was extracted from the cells
48 hours post-transfection. Western analysis was performed with an
anti-PBX3 antibody and anti-a-tubulin as loading control.
Representative Western blots are shown and the results from the
densitometric analysis of three independent experiments are
presented in the histograms above (mean ± SD (n = 3)). A t-test
(paired two samples of mean) was performed and a two-tailed P
value < 0, 05 is indicated with a *. B) Let-7d mimic transfection of
C4-2B and RWPE-1 cells followed by detection of endogenous PBX3
levels by Western analysis. Anti-a-tubulin (C4-2B) and anti-PRKAR1A
(RWPE-1) antibodies were used as loading controls. Representative
Western blots are presented.
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Figure 4 PBX3 is a Let-7d target gene. A) A schematic
presentation of the 3’UTR sequence of PBX3 included in the
reporter plasmids. The mature Let-7d sequence is shown
underneath and the predicted Let-7d binding region is underlined.
The underlined nucleotides are deleted in the pMIR-Luc-PBX3-3’UTR-
Mut plasmid. B) LNCaP cells transiently transfected with either
empty vector (pMIR-Luc) or reporter plasmids containing the 3’UTR-
PBX3 in either the correct (pMIR-Luc-PBX3 3’UTR) or the inverse
orientation (pMIR-Luc-PBX3 3’UTR-Rev) were harvested and reporter
activity measured. C) Reporter plasmids containing the 3’UTR of
PBX3 with either the wild-type binding site of Let-7d present (pMIR-
Luc-Pbx3 3’UTR marked PBX3 3’UTR) or deleted (PBX3 3’UTRmut)
were transfected into LNCaP cells in the absence or presence of
5·10-8 M Let-7d mimic. The cells were harvested 48 hours post-
transfection. Luciferase activity adjusted for b-galactosidase activity
is shown in the histograms. Data are presented as mean ± SD (n =
3) relative to LNCaP cells transfected with PBX3 3’UTR. A t-test
(paired two samples of mean) was performed and a two-tailed p-
value < 0, 05 is indicated with a *.
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PBX3 expression and Let-7d levels in prostate specimens
Tissue micro-array slides with 21 benign and 30 malig-
nant tissue cores from patient’s having undergone
laparoscopic prostatectomy at Oslo Urological Univer-
sity Clinic (Norway) were analyzed for PBX3 expression
by immunohistochemical staining as shown in Figure
6A. PBX3 was detected in the nucleus of basal cells in
benign areas, whereas cytoplasmic expression of PBX3
was observed in malignant prostate cancer. Scoring of
the staining intensities showed that the level of PBX3
was up-regulated in malignant compared to benign tis-
sue (Figure 6B). A Pearson’s chi-squared test was pre-
formed showing a significant difference (p < 0.001)
between the PBX3 expressions in benign compared to
malignant prostate cancer tissue.
We observed an up-regulation of PBX3 at the protein
level in malignant prostate cancer, whereas analysis of
Let-7d expression in 18 matched benign and malignant
samples from prostatectomy specimens showed down-
regulation of Let-7d in malignant compared to benign
tissue samples (Figure 6C).
Discussion
This study shows that PBX3 is post-transcriptionally
regulated by androgen in prostate cancer cell lines.
Furthermore, PBX3 is identified as a target of Let-7d, an
androgen regulated microRNA, indicating that androgen
regulates PBX3 expression through Let-7d. PBX3 was
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Figure 5 Androgen regulation of Let-7d in prostate cancer cell
lines. LNCaP, C4-2 and RWPE-1 cells were stimulated with 10-10M
R1881 (R1881) or left untreated (Ctr) for 24 hours. Let-7d levels were
quantitated using sqRT-PCR. RNU6B microRNA was used for
normalization. Data are presented as mean ± SD (n = 3) relative to
the corresponding untreated cells. A t-test (paired two samples of
mean) was performed and a two-tailed P value < 0, 05 is indicated
with a *.
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Figure 6 Expression of Let-7d and PBX3 in human prostate
cancer specimens. A) Representative images of benign and
malignant prostate tissue immunohistochemically stained with anti-
human PBX3 antibody. B) TMA slides, with benign (n = 21) and
malignant (n = 30) prostate tissue cores, were
immunohistochemically stained with anti PBX3 antibody and scored
according to staining intensity from 0 to 3. B) Levels of Let-7d in
benign and malign prostate tissue samples (n = 18) from Oslo
Urological University Clinic were quantified by sqRT-PCR. RNU6B
microRNA was used for normalization. A Pearson’s chi-squared test
was performed showing a significant difference (p < 0.001). Vertical
lines in each box represent the median value and Whiskers show
the 95% confidence interval.
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up-regulated and Let-7d was down-regulated in prostate
cancer compared to normal epithelial prostate cells.
Androgen regulation of PBX3 was predominantly
post-transcriptional since no regulation of PBX3 at the
mRNA level following androgen stimulation was
detected. This is in contrast to the regulation of PBX1,
previously identified as a target gene for PLZF (promye-
locytic leukemia zinc finger), an early androgen respon-
sive gene [21]. Kikugawa and colleagues showed that
PBX1 was regulated after androgen treatment in DU145
cells transfected with the androgen receptor, indicating
that PBX1 was indirectly regulated by androgens
through PLZF. Whereas putative PLZF-binding sites are
present in the PBX1 promoter [22], a preliminary analy-
sis using the TFSEARCH software by our group gener-
ated no putative PLZF-binding sites in the upstream
region of the human PBX3 gene (data not shown) [23].
Previous studies have shown that all-trans retinoic acid
induced the expression of PBX1 at mRNA level in P19
embryonic carcinoma cells, whereas the PBX3 mRNA
level remained unchanged. The protein level of PBX3
was, however, induced by all-trans retinoic acid [24,25].
Interestingly, our data indicate that androgen regulates
the expression of PBX3 independently of AR as the
R1881 effect was observed in LNCaP cells transfected
with siRNA targeting AR and in RWPE-1 cells that
express very low levels of AR (not detectable on Wes-
tern blot) [26]. The androgen effect was also seen in the
presence of bicalutamide, an anti-androgen. Although
most effects of androgens are mediated by AR, some
responses like rise in intracellular calcium and cAMP
concentrations seem to take place independent of AR in
some cell types [27]. Further studies are needed to
explore the molecular mechanisms involved in AR inde-
pendent effects of androgens.
Since androgen had no effect on the PBX3 mRNA
level or protein stability in our study, we hypothesized
that androgen might regulate the protein synthesis of
PBX3 through microRNA. MicroRNAs are short oligo-
nucleotide, 28-24 nucleotides long, that binds to the 3’
untranslated region (3’UTR) of their target genes. The
binding of a mature microRNA to the RNA-inducing
silencing complex (RICS) can initiate translational inhi-
bition and RNA degradation. Putative binding sites for
three microRNAs, miR-101, miR-222 and Let-7d were
identified in the 3’UTR region of the PBX3 gene by
using three different microRNA target prediction soft-
ware. In this study, we have focused on Let-7d, since
transfection with Let-7d mimic, in contrast to transfec-
tion of miR-101 and miR-222 mimics, reduced the pro-
tein level of endogenous PBX3 in LNCaP cells.
Let-7d is a microRNA that is part of the Let-7 family
[28]. Many of the 13 Let-7 family members have been
shown to be regulated in prostate cancer [29-33].
Interestingly, Let-7d was recently identified as an andro-
gen-regulated microRNA in LNCaP and LAPC-4 cell
lines following microarray analysis, giving support to
our data indicating androgen regulation of PBX3 synth-
esis through Let-7d [34]. The Let-7 family is involved in
normal development and differentiation, and has been
shown to act as tumor suppressors in many human can-
cers [28]. In LNCaP cells, Let-7a was recently shown to
have an anti-proliferative effect [35]. We were able to
detect reduced viability in LNCaP cells transfected with
Let-7d (data not shown), demonstrating the possible
tumor suppressor function of the Let-7 family in pros-
tate cancer, a function that is supported by the observed
down-regulation of Let-7d expression in malignant com-
pared to benign prostate cancer tissue. Two studies have
previously reported down-regulation of Let-7d in malig-
nant compared to benign prostate tissue using microar-
ray analysis [29,30] whereas a third study by Volinia et.
al. showed an up-regulation of Let-7d in malignant
prostate tissue [36].
Whereas Let-7d expression was reduced in prostate
cancer, increased expression of PBX3 was observed in
malignant versus benign prostate tissue by immunohis-
tochemical staining of prostate specimens with an anti
human PBX3 specific monoclonal antibody. We
observed nuclear staining of basal cells in benign pros-
tate tissue and no detectable staining of luminal cells.
However in malignant tissue, staining was detected both
in the cytoplasm and nucleus of secretory luminal cells.
Previous work by Crijns and colleagues [37] reported
increased PBX immunohistochemical staining in both
cytoplasm and nuclei of ovarian tumor cells using an
anti-PBX1/2/3/4 antibody, which does not differentiate
between the different PBX members. Future work will
show whether PBX3 has a potential role as a biomarker
or drug target in prostate cancer as shown in other
types of cancer [14-17].
Conclusions
Here we demonstrate for the first time that PBX3 is up-
regulated in malignant prostate tissue. The presented
results show that androgen regulates PBX3 expression
via Let-7d in the prostate cancer cell lines tested. This is
of interest in light of the role of androgens in prostate
cancer progression and the role of microRNA in regu-
lating gene expression at the post-transcriptional level.
The putative involvement of PBX in regulation of differ-
entiation and steroidogenesis makes the PBX members
interesting candidates for therapeutic targeting in later
stages of prostate cancer. It would therefore be of inter-
est to establish whether disruption of the PBX transcrip-
tion complex formation using PBX-binding peptides like
HXR9, can halt progression of advanced stages of pros-
tate cancer.
Ramberg et al. Molecular Cancer 2011, 10:50
http://www.molecular-cancer.com/content/10/1/50
Page 6 of 10
Materials and methods
Cell culture
LNCaP and RWPE-1 cells were purchased from ATCC
(Rockville, MD) and cultured in RPMI 1640 medium
supplemented with 10% (v/v) fetal bovine serum (FCS)
or Keratinocyte-SFM medium from Invitrogen (Carls-
bad, CA, USA) supplemented with 2.5 μg Epidermal
Growth Factor (EGF) and 25 mg Bovine Pituitary
Extract (BPE), respectively. The LNCaP C4-2B cell line
was kindly provided by professor Leland W.K. Chung at
Emory University, Atlanta, Georgia. C4-2B cells were
cultured in T-medium (D-MEM:F-12 (1:1) + L-Gluta-
min+15 mM HEPES (Invitrogen, Carlsbad, CA) supple-
mented with 5 μg/ml insulin, 0,0136 ng/ml T3, 5 μg/ml
apo-transferin, 0,25 μg/ml biotin, 25 μg/ml adenine, 50
μg/ml streptomycin, 50 μg/ml penicillin and 5% FCS).
All the cell lines were maintained at 37°C in a 5% CO2-
humidified incubator. CSS was prepared by charcoal
treatment of FCS under agitation at 4°C overnight, fol-
lowed by centrifugation and sterile filtration. R1881/
Methyltrienolone was purchased from Roussel-UCLAF
(Romainville, France) and bicalutamide was purchased
from Astra Zeneca (Cheshire, UK). All other compounds
were from Sigma (St. Louis, MO) unless otherwise
specified.
Stimulation of prostate cancer cell lines
LNCaP and C4-2 were pre-treated for 3 days (Figure 1,
2) or 24 hours (Figure 5) with medium containing 10%
CSS before stimulation. The cells were treated with 10-
10M R1881 (synthetic androgen), 10-8M bicalutamid
and/or 10 μg/ml cycloheximide. Cycloheximide and
bicalutamide was added 2 hours before R1881. Cells
incubated in 10% CSS throughout the experiment were
used as controls. RWPE-1 cells were not pre-treated
since they are cultivated in serum free medium.
Semi-Quantitative Real-Time RT-PCR (sqRT-PCR)
Total RNA was isolated using Trizol™ from Invitrogen
(Carlsbad, CA,). 100 ng of total RNA were included in a
one-step RT-PCR reaction using QuantiTect SYBR
Green RT-PCR kit from Qiagen (Hilden, Germany) that
was performed using MJ Research DNA Engine Opticon
Continuous Fluorescence Detection System from MJ
Research Inc. (Walthan, MA). RT-PCR cycle conditions
were as follows; reverse transcription at 50°C for 30 min
and inactivation step 95°C for 15 min, followed by 40
PCR cycles (15 s at 94°C, 30 s at 55°C, 30 s at 72°C),
and a final extension at 72°C for 5 min followed by a
melting curve analysis. G6PD was used for normaliza-
tion. The ΔΔCt formula was used as described in the
protocol from Applied Biosystems (Foster City, CA).
The following primers were used; G6PD [NM_000402]:
tgcatgagccagataggc and acagggaggagatgtggttg; PBX3
[NM_006195]: gcattaatcattacatcg and tgacagttcaggg-
catgttt. The Taqman microRNA assay from Applied Bio-
systems was used to detect and quantitate Let-7d
expression. 10 ng of total RNA were used in a two step
RT-PCR reaction with the hsa-Let-7d Taqman® Micro-
RNA Assay kit (Applied Biosystems, Cat. no 4395394),
Taqman® MicroRNA Reverse Transcription kit (Applied
Biosystems, Cat. no 4366596) and Taqman® 2X Univer-
sal PCR Master Mix (Applied Biosystems, Cat. no
4324018) in accordance with the manufacturer’s proto-
cols. The RNU6B Taqman® MicroRNA Assay (Applied
Biosystems, Cat. no 4373381) was used for normaliza-
tion. The ΔΔCt and ΔCt formulas were used as
described in the protocol from Applied Biosystems (Fos-
ter City, CA).
Protein extraction and Western analysis
Cells were harvested in PBS and lysed in RIPA buffer
(25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40,
0.1% SDS) and Complete protease inhibitor Tablets
from Roche (Mannheim, Germany) followed by 30 min
rotation at 4°C. The lysate was centrifuged at 10,000 g
for 30 min and the amount of protein in the superna-
tant was estimated by Bradford protein assay kit from
Bio-Rad Laboratories (Hercules, CA). Protein extracts
(50 μg/lane) and MagicMark (Invitrogen Carlsbad, CA)
were separated on NuPAGE 10% or 4-12% gradient
Bis-Tris gels from Invitrogen (Carlsbad, CA) and trans-
ferred to PVDF membranes purchased from Millipore
Corporation (Billerica, MA) by wet electro blotting.
Membranes were blocked in 5% (w/v) skimmed milk
powder in Tris-buffered saline containing 0.1% (v/v)
Tween-20 (TBST) for 2 hours at room temperature
(RT), and then incubated over night at 4°C with the
appropriate primary antibody diluted in TBST. Primary
antibodies used were mouse monoclonal anti-PBX3
antibody from Abnova Corporation (Heidelberg, Ger-
many), anti-PRKAR1A antibody from Transduction
Laboratories (Franklin Lakes, NJ), anti-ERK 1/2 from
Cell Signaling Technology (Boston, MA) and mouse
monoclonal anti-a-Tubulin antibody from Sigma (St.
Louis, MO). The NKX3.1 antibody was kindly provided
by professor Fahri Saatcioglu at Department of Mole-
cular Biosciences, University of Oslo, Norway. Mem-
branes were washed 3 × 10 min with TBST and
further incubated for 1 hour with anti mouse or anti
rabbit IgG horse-radish peroxidase-conjugated second-
ary antibodies from Jackson ImmunoResearch Ltd
(Cambridgeshire, UK). After washing 3 × 10 min,
membranes were developed using Immobilon™ Wes-
tern by Millipore (Billerica, MA). Images were gener-
ated using a Hamamatsu Digital Camera from Syngene
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(Cambridge, UK), and quantified using the Multi
Gauge software from FujiFilm (Bedford, UK).
Prostate tissue specimen
Matched benign and malignant prostate tissues for
mRNA analysis and immunohistochemical staining were
derived from radical prostatectomy of 18 and 30 pros-
tate cancer patients, respectively, treated at Oslo Urolo-
gical University Clinic and obtained from “The Prostate
Biobank - a resource for urological research in Norway”
(10974). The tissue samples were treated with RNALater
at 4°C overnight according to the manufactures protocol
(Qiagen, Hilden, Germany) and stored at -80°C. The
pathology of the samples was verified by an experienced
uropathologist (AS). Written consent was obtained from
all patients and the project was approved by The Regio-
nal Committee for Medical and Health Research Ethics.
Immunohistochemistry
Immunohistochemical staining of paraffin embedded tis-
sue sections were performed according to the manufac-
tures protocol using Ultravision One detection system
from LabVision (Fremont, CA) and IHC Select manual
staining system from Chemicon (Temecula, CA). Tissue
microarray (TMA) slides were deparaffinised and anti-
gen retrieved in citrate buffer (pH 6) for 30 min at 100°
C in the PT module from Lab-Vision (Suffolk, UK). The
TMA slides were incubated with anti human PBX3 anti-
body (dilution 1:50). Non-immune IgG from Vector
Laboratories Inc. (Burlingame, CA) was used as negative
control. Slides were treated for 70 s in haematoxylin.
Manual scoring of the staining was done by an experi-
enced pathologist who also verified all pathological grad-
ings (AS). The tissue microarray of specimens from
radical prostatectomies contained benign and malignant
tissue from 30 patients. Images were captured using
Leica DM RA2 microscope and Leica DC 300F camera.
Plasmids
The PBX3-SPORT6 expression vector containing a full
length cDNA clone of PBX3 from Imagene (Imagene,
IRATp970H04107D) was used for overexpression of
PBX3. The pMIR-REPORT™ miRNA Expression Repor-
ter Vector System (Applied Biosystems, Cat. no
AM5795) consisting of pMIR-REPORTER™ Luciferase
and pMIR-REPORTER™ b-gal Control Plasmids was
used in this study. The former (pMIR-Luc) was used to
generate luciferase reporter constructs with the PBX3
3’untranslated regions (nucleotides 1275-2760
NM_006195). The following primer set, PBX3 3’UTR;
agacgggagctcatcaatcagacgggaggctac and agaataaagcttcat-
tagaatcaccgccacaa, was used to generate a PBX3-3’UTR
amplicon from the PBX3-Sport6 vector and cloned into
the pMIR-Luc repoter vector. A reporter vector with the
PBX3 3’UTR sequence in the reverse orientations was
also designed with the PBX3 Rev3’UTR primer set;
tgggactagtcctcattagaatcaccgccacaa and tcttataagctttcaat-
cagacgggaggctac. The GeneAmp High Fidelity PCR sys-
tem from Applies Biosystems was used according to the
manufacturer’s protocol. The predicted Let-7d seed
binding region, tacctca, of PBX3 3’UTR was deleted
using the QuickChange ll Site Directed Mutagenesis kit
(Stratagene, cat. No 200523). The protocol from the
manufacturer was followed and the two mutagenic dele-
tion primers designed and used in the construction of
the pMIR-PBX3-3’UTR-Mut were ccaatcaaaacacagctt-
tattgcgaactcatacaaacc and ggtttgtatgagttcgcaa-
taaagctgtgttttgattgg. All the plasmids constructed were
verified by sequencing at GATC Biotech (GATC Bio-
tech, Germany).
Transfection and Luciferase assay
Cells were seeded on either Petri dishes (10 cm) at 1 × 106
cells per dish, 6 wells plates at 300 000 cells per well or 96
well-plates at 5000 cells per well and cultured for 3 days in
complete medium. Cells were transfected with the plas-
mids mentioned above. Small interfering RNA (siRNA)
against AR (Dharmacon, Cat no. KROAA-005852) and
miRNA hsa-Let-7d miRIDIAN Mimic (Dharmacon, Cat.
no C-300478-07), hsa-Let-7d miRIDIAN Mimic Hairpin
Inhibitor (Dharmacon, Cat. no C-300478-08) and miRI-
DIAN microRNA Negative control 1 (Dharmacon, Cat. no
CN-001000-01-05). DharmaFECT™ Duo Transfection
reagent (Dharmacon Cat. no. T- 2010-03), Dharma-
FECT™ 3 (Dharmacon Cat. no. T- 2003-03) or Lipofecta-
mine 2000 (Invitrogen) were used according to the
manufactures protocols with minor modifications. Cells
were incubated in medium with serum and without anti-
biotics for 2 hours before transfection. The transfection
medium was changed after 4 hours of transfection to med-
ium with serum and without antibiotics and further incu-
bated for 24 or 48 hours. Luciferase activity was measured
using a Luciferase assay system (cat. no.1501, Promega,
Madison, WI). The beta-galactosidase assay of the pMIR-
REPORTER™ b-gal Control Plasmid was performed with
Galacto Plus and Emerald reagents (Applied Biosystems).
We followed the protocol according to the manufacturer.
We used a Luminometer (TD-20/20 Turner Designs, Sun-
nyvale, CA) to measure the luciferase and b-galactosidase
activities.
Additional material
Additional file 1: Figure S1. Regulation of PBX3 protein level by
DHT in LNCaP. A) LNCaP cells were pre-treated for 3 days with 10% CSS
and stimulated with dihydrotestosterone (DHT) with different
concentrations as indicated in the figure for 48 hours. The Western blot
was probed with an anti-PBX3 antibody. B) A representative Western blot
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of LNCaP cells stimulated with 10-10 M R1881 for 1-4 days using an anti-
PBX1/2/3/4 antibody.
Additional file 2: Figure S2. PBX3 is post-transcriptionally regulated
by androgen. LNCaP cells were pre-treated for 3 days with medium
containing 10% CSS. Cells were then stimulated or left untreated (CSS).
A) Total RNA was extracted after 48 hours of 10-10M R1881 (R1881) and/
or 10-8M bicalutamide (R1881 + Bic or Bic) treatment to determine the
effect of R1881 on the expression levels of PBX3 mRNA by sqRT-PCR
relative to CSS. B) LNCaP cells were either left untreated (CSS), stimulated
with 10-10M R1881 (R1881) alone or in combination with 10 μg/ml
cycloheximide (R1881 + Cyc) for 48 hours. Cells only stimulated with
cycloheximide (Cyc) are shown as control. The cells were pre-treated
with cycloheximide for 2 hours before adding 10-10M R1881. Western
blots were probed with anti- PBX3 antibody and densitometrically
analysed. Anti a-tubulin antibody was used as loading control. Data is
presented as mean ± SD (n = 3).
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